查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853459

基因合成市場按產品、技術、應用和最終用戶分類－2025-2032年全球預測

Gene Synthesis Market by Product, Technology, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基因合成市場規模將達到 109.4 億美元，複合年成長率為 11.19%。

主要市場統計數據
基準年 2024 46.8億美元
預計年份：2025年 51.9億美元
預測年份：2032年 109.4億美元
複合年成長率 (%) 11.19%

為下一代基因合成奠定基礎，並闡明經營團隊必須優先考慮的策略要務，以將能力轉化為競爭優勢。

基因合成領域正處於快速技術創新、不斷擴展的應用需求以及對通量和精度日益提高的期望交匯點。自動化、酵素法和高保真組裝技術的最新進展降低了實驗室和服務供應商的進入門檻，同時也提高了設備、試劑和服務產品的性能基準值。在此背景下，企業管理者不僅需要了解正在湧現的技術，還需要了解這些技術如何轉化為營運效率、法規遵循和合作夥伴選擇標準。

為了優先發展可擴展的工作流程，企業正在重新評估其採購和研發重點，強調能夠縮短從設計到產品週期的整合解決方案。數位設計工具與物理合成工作流程的整合創造了新的競爭優勢，使得分子生物學家、自動化工程師和資料科學家之間的跨學科合作成為核心競爭力。因此，企業領導者應將基因合成視為一項策略能力，而非僅將其視為一種戰術性採購類別，以支援產品平臺、診斷平台和合成生物學舉措。

自動化、酵素創新和一體化商業化模式的融合如何重塑基因合成領域的能力和競爭地位

過去幾年，隨著自動化和酶促技術的創新從實驗室演示走向可部署平台，產業格局發生了翻天覆地的變化。這些變化從根本上改變了各機構對通量、可重複性和單次反應成本的考量。自動化已不再局限於液體處理，而是擴展到整合序列設計、合成、組裝和品管的端到端工作流程，從而縮短了週期時間，並支援更多迭代實驗。

同時，酶促合成路線和先進的基於PCR的組裝方法為傳統化學合成提供了替代方案，減少了有害廢棄物，並提高了構建更長分子結構的可擴展性。這些技術變革伴隨著商業化模式的轉變，包括設備和試劑的整合、複雜結構即服務模式的擴展，以及平台提供者與終端用戶之間更深入的夥伴關係。監管考慮和負責任的創新框架也日益重要，促使提供者在其硬體和軟體中整合合規功能。總而言之，這些發展正在將競爭優勢轉移到那些能夠提供整合化、檢驗且易於使用的工作流程，並滿足科學和營運需求的組織手中。

預見關稅對基因合成生態系統內的採購、供應鏈韌性與合作研發策略的連鎖反應

美國2025年實施的關稅政策立即對基因合成工作流程中使用的設備、試劑和特殊耗材的全球供應鏈波動。採購團隊迅速採取行動，審查供應商契約，加快雙源採購策略的實施，並重新評估庫存政策，以應對關稅帶來的成本波動。同時，一些供應商調整了產品系列和分銷策略，透過本地化生產和庫存區域化來減輕關稅的影響。

除了採購之外，關稅環境也影響了研發計畫和共同研究模式。開展跨境合作的公司調整了時間表和物料流以避免中斷，而另一些公司則加快了對國內生產能力的投資以降低風險。這些調整通常需要商務、法律和技術團隊密切合作，以評估合規性、調整定價結構並管理前置作業時間預期。

隨著時間的推移，相關人員對供應鏈風險的視角變得更加細緻，將關稅風險納入更廣泛的韌性框架，涵蓋單一來源採購風險、物流限制、監管複雜性等諸多面向。這種供應鏈管治的綜合方法已成為企業的策略差異化優勢，這些企業必須在創新速度與可預測的設備、酵素、寡核苷酸和專業服務取得之間取得平衡。因此，韌性規劃已轉向將關稅情境納入資本設備決策、長期籌資策略和夥伴關係關係選擇。

整合的細分洞察揭示了產品、技術、應用和最終用戶等方面的差異如何驅動產品藍圖和競爭優勢的形成。

這種細分方法為基因合成生態系統中的投資和產品開發優先排序提供了一個視角，透過對產品、技術、應用和終端用戶群體的細緻理解，揭示了價值所在。基於產品，市場細分為儀器、試劑及耗材及服務。儀器細分包括自動化克隆儀、DNA合成儀、微陣列平台和聚合酵素連鎖反應熱迴圈儀。試劑及耗材細分包括緩衝液及其他耗材、酵素套件、寡核苷酸。服務細分包括基礎基因合成、密碼子最佳化、基因克隆、基因文庫建構和誘變服務。這一層級凸顯了儀器製造商在可靠性、通量和整合性方面的競爭；試劑供應商在配方穩定性、批間一致性和法規文件方面的競爭；以及服務供應商在智慧財產權保護、交付時間和設計專業知識方面的差異化優勢。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 藥物研發開發平臺中高通量自動化基因合成​​平台的應用日益增多
  • 酵素DNA合成技術的出現降低了組裝長片段所需的成本和時間。
  • 整合人工智慧演算法以最佳化寡核苷酸設計並減少錯誤
  • CAR-T細胞和基因治療研發領域對客製化基因合成​​服務的需求日益成長
  • 擴大區域基因合成製造地，以因應供應鏈中斷和本地化需求
  • 在全球基因合成服務提供者中實施標準化的品管和監管合規框架
  • 夥伴關係模式，使學術機構能夠獲得用於合成生物學研究的商業平台。
  • 透過整合雲端基礎的LIMS和基因組裝設計軟體，加速實驗室的工作流程。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因合成產品市場

  • 裝置
    • 自動克隆設備
    • DNA合成器
    • 微陣列平台
    • 聚合酵素連鎖反應熱迴圈儀
  • 試劑和耗材
    • 緩衝劑和其他消耗品
    • 酵素和套件
    • 寡核苷酸
  • 服務
    • 基礎基因合成
    • 密碼子最佳化
    • 基因複製
    • 基因文庫構建
    • 誘變服務

9. 按技術分類的基因合成市場

  • 化學合成
    • H-膦酸酯合成
    • 亞磷醯胺合成
  • 酵素合成
    • 吉布森組裝
    • 金門集會
    • 連接酶鍊式反應
  • 基於PCR的合成
    • 聚合PCR
    • 連接酶鍊式反應
    • 重疊延伸PCR

第10章 基因合成市場（依應用領域分類）

  • 抗體和疫苗生產
  • 工業生物技術
  • 分子診斷
  • 幹細胞和細胞株工程
  • 合成生物學

第11章 基因合成市場（依最終用戶分類）

  • 學術研究機構
  • 臨床診斷實驗室
  • 合約研究組織
  • 製藥和生物技術公司

第12章 基因合成市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因合成市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國基因合成市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • GenScript BIoTech Corporation
    • Twist Bioscience Corporation
    • Integrated DNA Technologies, Inc.
    • Eurofins Genomics GmbH
    • Agilent Technologies, Inc.
    • Merck KGaA
    • Sangon BIoTech Co., Ltd.
    • Bio Basic Inc.
    • Synbio Technologies Co., Ltd.
Product Code: MRR-3A2E844FEB5F

The Gene Synthesis Market is projected to grow by USD 10.94 billion at a CAGR of 11.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.68 billion
Estimated Year [2025] USD 5.19 billion
Forecast Year [2032] USD 10.94 billion
CAGR (%) 11.19%

Setting the stage for next-generation gene synthesis and the strategic imperatives that executives must prioritize to convert capability into competitive advantage

The gene synthesis landscape sits at the intersection of rapid technological innovation, expanding application demand, and increasing expectations for throughput and accuracy. Recent advances in automation, enzymatic methods, and high-fidelity assembly techniques have lowered barriers to entry for laboratories and service providers alike, while simultaneously raising the performance baseline for instruments, reagents, and service offerings. In this context, executives must understand not only which capabilities are emerging but also how those capabilities translate into operational efficiencies, regulatory compliance, and partner selection criteria.

As organizations prioritize scalable workflows, they are re-evaluating procurement and R&D priorities to emphasize integrated solutions that shorten design-to-product cycles. The convergence of digital design tools with physical synthesis workflows has created new vectors for competitive differentiation, making cross-disciplinary collaboration between molecular biologists, automation engineers, and data scientists a core competency. Consequently, leaders should view gene synthesis not merely as a tactical procurement category but as a strategic capability that underpins product pipelines, diagnostic platforms, and synthetic biology initiatives.

How converging automation, enzymatic innovations, and integrated commercialization models are reshaping capabilities and competitive positioning across gene synthesis

The past several years have seen transformative shifts as automation and enzymatic innovations matured from laboratory proofs to deployable platforms. These shifts have fundamentally altered how organizations approach throughput, reproducibility, and cost per reaction. Automation has extended beyond liquid handling to incorporate end-to-end workflows that integrate sequence design, synthesis, assembly, and quality control, thereby compressing cycle times and enabling more iterative experimentation.

Simultaneously, enzymatic synthesis routes and refined PCR-based assembly methods have introduced alternatives to traditional chemical synthesis that reduce hazardous waste and improve scalability for longer constructs. These technical shifts are accompanied by changes in commercialization models: integrated instrument-plus-reagent offerings, expanded as-a-service capabilities for complex constructs, and deeper partnerships between platform providers and end users. Regulatory considerations and responsible innovation frameworks have also gained prominence, prompting providers to bake compliance-ready features into hardware and software. Taken together, these developments are shifting competitive advantage toward organizations that can deliver integrated, validated, and user-friendly workflows that meet both scientific and operational expectations.

Anticipating the cascading effects of tariff measures on procurement, supply chain resilience, and collaborative R&D strategies within gene synthesis ecosystems

United States tariff actions introduced in 2025 created immediate ripples across global supply chains for instruments, reagents, and specialty consumables used in gene synthesis workflows. Procurement teams responded by reviewing supplier contracts, accelerating dual-sourcing strategies, and re-evaluating inventory policies to buffer against duty-related cost volatility. In parallel, some vendors revised product portfolios and distribution strategies to mitigate tariff impacts through localized production or regionalized inventory hubs.

Beyond procurement, the tariff environment influenced R&D planning and collaboration models. Organizations with cross-border collaborations adjusted timelines and material flows to avoid disruption, while others accelerated investment in domestic manufacturing capabilities to reduce exposure. These adjustments often required closer alignment between commercial, legal, and technical teams to assess compliance, adapt pricing structures, and manage expectations for lead times.

Over time, stakeholders shifted toward a more granular view of supply chain risk that included tariff exposure as part of a broader resilience framework encompassing single-sourcing risk, logistical constraints, and regulatory complexity. This integrated approach to supply chain governance has become a strategic differentiator for companies that must balance innovation velocity with predictable access to instruments, enzymes, oligonucleotides, and specialized services. Consequently, resilience planning now integrates tariff scenarios as part of capital equipment decisions, long-term procurement strategies, and partnership selection.

Integrated segmentation insights revealing how product, technology, application, and end-user distinctions drive product roadmaps and competitive differentiation

Segmentation provides a lens for prioritizing investment and product development across the gene synthesis ecosystem, and nuanced understanding of product, technology, application, and end-user tiers reveals where value accrues. Based on Product, market is studied across Instruments, Reagents & Consumables, and Services. The Instruments is further studied across Automated Cloning Instruments, DNA Synthesizers, Microarray Platforms, and Thermal Cyclers. The Reagents & Consumables is further studied across Buffers & Other Consumables, Enzymes & Kits, and Oligonucleotides. The Services is further studied across Basic Gene Synthesis, Codon Optimization, Gene Cloning, Gene Library Construction, and Mutagenesis Services. This layering highlights that instrument manufacturers compete on reliability, throughput, and integration, whereas reagents providers compete on formulation stability, lot-to-lot consistency, and regulatory documentation, and service providers differentiate through IP protection, turnaround times, and design expertise.

Based on Technology, market is studied across Chemical Synthesis, Enzymatic Synthesis, and PCR Based Synthesis. The Chemical Synthesis is further studied across H-Phosphonate Synthesis and Phosphoramidite Synthesis. The Enzymatic Synthesis is further studied across Gibson Assembly, Golden Gate Assembly, and Ligase Chain Reaction. The PCR Based Synthesis is further studied across Assembly PCR, Ligase Chain Reaction, and Overlap Extension PCR. This technology taxonomy clarifies where technical trade-offs emerge: chemical routes offer mature, high-fidelity oligonucleotide production, enzymatic methods promise greener and scalable assembly for larger constructs, and PCR-based approaches remain essential for bespoke construct fabrication and iterative design cycles.

Based on Application, market is studied across Antibody & Vaccine Production, Industrial Biotechnology, Molecular Diagnostics, Stem Cell & Cell Line Engineering, and Synthetic Biology. Application-driven priorities shape performance requirements, such that vaccine development emphasizes speed and regulatory traceability, diagnostics emphasize reproducibility and sensitivity, and synthetic biology emphasizes modularity and scalability. Based on End-User, market is studied across Academic & Research Institutes, Clinical Diagnostics Laboratories, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies. Each end-user category imposes distinct purchasing rationales and support expectations: academic labs prioritize flexibility and cost-effectiveness, clinical labs prioritize accreditation and validation, CROs prioritize throughput and service reliability, and commercial biotech firms prioritize long-term supplier partnerships and integrated solutions.

Taken together, these segmentation layers inform commercialization strategies. Leaders that align product roadmaps and service models to the specific technical and operational priorities of target end users capture higher adoption and deeper partnerships. Moreover, cross-segmentation thinking - for example, mapping enzymatic synthesis advantages to synthetic biology and CRO workflows - clarifies where to invest in validation, training, and co-development to accelerate uptake.

Regional strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape adoption, regulation, and localized supply dynamics

Regional dynamics exert a strong influence on adoption patterns, regulatory expectations, and the structure of partnerships across the gene synthesis value chain. In the Americas, investment in domestic manufacturing and translational research capabilities continues to support rapid adoption of advanced instruments and integrated service offerings. This region often leads in regulatory clarity for clinical applications, which in turn encourages commercialization of high-throughput synthesis solutions and close coordination between vendors and large pharmaceutical partners.

In Europe, Middle East & Africa, the ecosystem reflects a mosaic of strong research hubs, varying regulatory approaches, and increasing emphasis on collaborative consortia that pool capacity for complex synthetic biology projects. Policy debates around biosecurity and responsible innovation have been particularly active here, prompting vendors to invest in transparency, auditability, and compliance-enabling features for their platforms. These investments facilitate cross-border collaborations while meeting heightened governance expectations.

Across Asia-Pacific, infrastructure expansion and targeted national strategies to support biotech industrialization are driving rapid uptake of both instruments and outsourced services. The emphasis on scaling local capability has encouraged suppliers to localize manufacturing and support, and it has increased the attractiveness of reagent formulations and instrument configurations optimized for high-volume production. Taken together, these regional nuances argue for differentiated go-to-market approaches, localized validation efforts, and region-specific partnership strategies to ensure relevance and operational continuity.

Competitive behaviors, partnership models, and product strategies that distinguish market leaders and influence long-term positioning in gene synthesis ecosystems

Leading organizations within the gene synthesis ecosystem now compete on a combination of technological depth, ecosystem partnerships, and service reliability rather than on single product features alone. Companies that invest in modular platforms that integrate design, synthesis, and quality control gain traction among customers seeking turnkey workflows. Similarly, reagent suppliers that provide robust technical documentation and extended stability data reduce friction for regulated end users and earn preference in clinical and industrial settings.

Partnership patterns have shifted toward co-development arrangements with academic centers and commercial biotech firms, enabling faster validation cycles and broader application coverage. In addition, a subset of companies are pursuing service-first models, offering high-touch synthesis and design services that serve as entry points for longer-term instrument or reagent adoption. Strategic M&A and selective licensing agreements have also emerged as mechanisms to acquire niche capabilities or to expand addressable application spaces. Leadership in this sector increasingly requires balancing capital investments in automation and manufacturing with investments in regulatory, quality, and customer success capabilities to translate technical innovation into repeatable commercial outcomes.

Practical strategic moves for leaders to accelerate commercialization, strengthen resilience, and translate innovation into durable competitive advantage in gene synthesis

Industry leaders should prioritize a set of practical moves that align innovation efficiency with supply chain resilience and customer-centric commercialization. First, invest in modular automation and validated workflows that reduce handoffs and accelerate repeatable outcomes, because operational consistency underpins both research reproducibility and clinical-grade applications. Second, develop robust supplier diversification strategies and localized support to mitigate tariff and logistics risks while maintaining predictable access to enzymes, oligonucleotides, and specialty consumables.

Third, embed regulatory and biosecurity considerations into product design and customer onboarding to address emerging governance expectations and to lower barriers for clinical and diagnostic adoption. Fourth, cultivate partnerships that combine platform capabilities with application-specific expertise, thereby enabling co-developed solutions for antibody and vaccine production, molecular diagnostics, and synthetic biology. Fifth, prioritize customer success functions that translate technical advantages into measurable workflow improvements; investing in training, validated protocols, and dedicated technical support creates stickiness and accelerates adoption. Finally, consider flexible commercial models, including instrument-as-a-service and managed synthesis offerings, to broaden accessibility and lower entry barriers for high-value end users. Collectively, these actions will enable organizations to convert technology potential into sustainable competitive advantage.

Transparent research methodology describing primary and secondary inputs, validation processes, and analytical frameworks used to derive the gene synthesis insights

This analysis synthesizes primary and secondary inputs through a structured methodology emphasizing source triangulation, expert validation, and transparent analytical frameworks. Primary input included structured interviews and workshops with subject-matter experts spanning molecular biology, automation engineering, quality assurance, and commercial leadership. These engagements informed the interpretation of technological trade-offs, product integration patterns, and end-user purchasing behaviors.

Secondary input drew on peer-reviewed literature, regulatory guidance documents, manufacturer technical disclosures, and public filings where available, with attention to cross-referencing claims against independent validation sources. Analytical frameworks included capability mapping across instruments, reagents, and services; technology maturity assessments for chemical, enzymatic, and PCR-based synthesis routes; and scenario-based stress testing for supply chain disruptions such as tariff changes.

Data synthesis emphasized reproducibility and traceability: key assumptions and data sources were recorded, and conclusions were validated during follow-up expert reviews to minimize interpretive bias. Where uncertainty persisted, alternative hypotheses were documented to support transparent decision-making. This approach ensures that the insights presented are grounded in both practitioner experience and documented evidence, and that users can assess relevance to their specific operational or strategic questions.

Synthesis of strategic takeaways and a forward-looking perspective on how stakeholders can navigate disruption and capitalize on gene synthesis advancements

The cumulative picture points to a gene synthesis landscape in which integrated workflows, resilient supply chains, and application-driven validation will determine who converts scientific innovation into commercial impact. Technological plurality - with chemical, enzymatic, and PCR-based methods each offering distinct advantages - requires strategic clarity about where to focus engineering and go-to-market efforts. At the same time, regional disparities in infrastructure, regulatory posture, and procurement practices demand localized execution plans rather than one-size-fits-all approaches.

To succeed, organizations must balance short-term operational resilience with long-term investments in modular automation, validated reagents, and customer-facing services. Collaboration across the value chain-between instrument makers, reagent suppliers, service providers, and end users-will accelerate the translation of capability into outcomes such as faster vaccine development cycles, higher-throughput diagnostic pipelines, and scalable synthetic biology applications. Ultimately, the winners will be those who align technical excellence with pragmatic commercialization strategies and who purposefully design for compliance, scalability, and customer adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of high-throughput automated gene synthesis platforms in pharmaceutical R&D pipelines
  • 5.2. Emergence of enzymatic DNA synthesis methods to reduce cost and time for long fragment assembly
  • 5.3. Integration of artificial intelligence algorithms for optimized oligonucleotide design and error reduction
  • 5.4. Growing demand for custom gene synthesis services in CAR-T and other cell and gene therapy development
  • 5.5. Expansion of regional gene synthesis manufacturing hubs to address supply chain disruptions and localization needs
  • 5.6. Implementation of standardized quality control and regulatory compliance frameworks across global gene synthesis providers
  • 5.7. Partnership models enabling academic institutions to access commercial gene synthesis platforms for synthetic biology research
  • 5.8. Adoption of cloud-based LIMS integration with gene assembly design software to accelerate laboratory workflows

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Synthesis Market, by Product

  • 8.1. Instruments
    • 8.1.1. Automated Cloning Instruments
    • 8.1.2. DNA Synthesizers
    • 8.1.3. Microarray Platforms
    • 8.1.4. Thermal Cyclers
  • 8.2. Reagents & Consumables
    • 8.2.1. Buffers & Other Consumables
    • 8.2.2. Enzymes & Kits
    • 8.2.3. Oligonucleotides
  • 8.3. Services
    • 8.3.1. Basic Gene Synthesis
    • 8.3.2. Codon Optimization
    • 8.3.3. Gene Cloning
    • 8.3.4. Gene Library Construction
    • 8.3.5. Mutagenesis Services

9. Gene Synthesis Market, by Technology

  • 9.1. Chemical Synthesis
    • 9.1.1. H-Phosphonate Synthesis
    • 9.1.2. Phosphoramidite Synthesis
  • 9.2. Enzymatic Synthesis
    • 9.2.1. Gibson Assembly
    • 9.2.2. Golden Gate Assembly
    • 9.2.3. Ligase Chain Reaction
  • 9.3. PCR Based Synthesis
    • 9.3.1. Assembly PCR
    • 9.3.2. Ligase Chain Reaction
    • 9.3.3. Overlap Extension PCR

10. Gene Synthesis Market, by Application

  • 10.1. Antibody & Vaccine Production
  • 10.2. Industrial Biotechnology
  • 10.3. Molecular Diagnostics
  • 10.4. Stem Cell & Cell Line Engineering
  • 10.5. Synthetic Biology

11. Gene Synthesis Market, by End-User

  • 11.1. Academic & Research Institutes
  • 11.2. Clinical Diagnostics Laboratories
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Gene Synthesis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Synthesis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Synthesis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. GenScript Biotech Corporation
    • 15.3.3. Twist Bioscience Corporation
    • 15.3.4. Integrated DNA Technologies, Inc.
    • 15.3.5. Eurofins Genomics GmbH
    • 15.3.6. Agilent Technologies, Inc.
    • 15.3.7. Merck KGaA
    • 15.3.8. Sangon Biotech Co., Ltd.
    • 15.3.9. Bio Basic Inc.
    • 15.3.10. Synbio Technologies Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE SYNTHESIS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENE SYNTHESIS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS GENE SYNTHESIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GENE SYNTHESIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. GENE SYNTHESIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENE SYNTHESIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENE SYNTHESIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENE SYNTHESIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CODON OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CODON OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CODON OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CODON OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CODON OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CODON OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE LIBRARY CONSTRUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE LIBRARY CONSTRUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE LIBRARY CONSTRUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE LIBRARY CONSTRUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE LIBRARY CONSTRUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE LIBRARY CONSTRUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ASSEMBLY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ASSEMBLY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ASSEMBLY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ASSEMBLY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ASSEMBLY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ASSEMBLY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OVERLAP EXTENSION PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OVERLAP EXTENSION PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OVERLAP EXTENSION PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OVERLAP EXTENSION PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OVERLAP EXTENSION PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OVERLAP EXTENSION PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS GENE SYNTHESIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS GENE SYNTHESIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS GENE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDD